Lantheus Q1 revenue rises 1.2%, beats expectations

Lantheus Holdings

07/05/2026 12:15

Overview

Radiopharmaceutical maker's Q1 revenue rose 1.2%, beating analyst expectations

Q1 adjusted EPS beat analyst expectations but declined 4.6% yr/yr

Company reaffirmed full-year 2026 revenue and adjusted EPS guidance

Outlook

Lantheus reaffirms 2026 revenue guidance of $1.4 bln to $1.45 bln

Company maintains 2026 adjusted fully diluted EPS guidance of $5.00 to $5.25

Phased geographic launch of PYLARIFY TruVu planned to begin in Q4 2026

Result Drivers

PRODUCT MIX - Revenue growth was driven by higher DEFINITY sales and the addition of Neuraceq, offset by a decline in PYLARIFY sales

PORTFOLIO FOCUS - Divestiture of SPECT business enabled greater focus on PET radiodiagnostics

Company press release: ID:nGNX6ptr0W

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$377.30 mln
$353.94 mln (11 Analysts)
Q1 Adjusted EPS
Beat
$1.46
$1.24 (11 Analysts)
Q1 EPS
$1.80


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)